BIOLIFE SOLUTIONS, INC. (NASDAQ:BLFS) Files An 8-K Results of Operations and Financial Condition
Item 2.02Results of Operations and Financial Condition.
On March 14, 2019, BioLife Solutions, Inc. (the “Company”) issued a press release announcing the financial results and operational highlights for the fourth quarter and full year ended December 31, 2018. A copy of the press release is furnished as Exhibit 99.1 to this current report on Form 8-K.
Item 8.01Other Events.
On March 14, 2019, the Company issued a press release announcing that the Company entered into an agreement to acquire Astero Bio Corporation, a privately-held company in the design, development and commercialization of novel automated thawing devices. A copy of the press release is furnished as Exhibit 99.2 to this current report on Form 8-K.
Item 9.01Financial Statements and Exhibits.
BIOLIFE SOLUTIONS INC Exhibit
EX-99.1 2 ex_137785.htm EXHIBIT 99.1 ex_137785.htm Exhibit 99.1 BioLife Solutions Announces Fourth Quarter and Full Year 2018 Financial Results Revenue Increased 79% for the Year to $19.7 Million Net Income of $2.9 Million Gained 84 New Direct Cell & Gene Therapy Customers Conference Call and Webcast Begin at 4:30 p.m. Eastern Time Today BOTHELL,…
To view the full exhibit click
About BIOLIFE SOLUTIONS, INC. (NASDAQ:BLFS)
BioLife Solutions, Inc. (BioLife) is engaged in the developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management application for shippers. The Company’s product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs; generic blood stem cell freezing and cell thawing media products; custom product formulation and custom packaging services; cold chain logistics services incorporating precision thermal packaging products and cloud-hosted Web applications, and contract aseptic manufacturing formulation, fill and finish services of liquid media products. Its products include HypoThermosol FRS, CryoStor, BloodStor, Cell Thawing Media, PrepaStor and biologistex cold-chain management service.